Proteomics signs national distribution deal with Healius
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. has signed a national distribution agreement with Healius for its Promarker® portfolio, making Healius the exclusive pathology distribution partner in Australia. Implementation activities will begin immediately, with a phased commercial rollout planned for the following financial year. This partnership marks the first national distribution agreement for Proteomics International, enhancing its market access for diagnostic tests.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd. on 6ix
In the deck
Earlier from Proteomics International Laboratories
- US patent secured for PromarkerEndo
- Proteomics Strategic Plan
- Restructure, Executive Appointment and Board Update
- Appendix 4D and Interim Financial Report
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Proteomics International Laboratories
- Change in substantial holding
- Australian patent for PromarkerEndo
- Appendix 4G and Corporate Governance Statement
- Appendix 4E and Annual Report
- PromarkerD and PromarkerEso Commercial Rollout Update
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories